Bristol-Myers, J&J on Deck to Negotiate Prices With Medicare

The drugmakers suing the US government in multiple courts to block drug price negotiations are doing so for good reason—they’re the ones that stand to lose the most in Medicare’s first-ever plan to control the cost of medicines it spends the most on.

Medicare is expected to reveal the first 10 drugs to be subject to price negotiation by Sept. 1. Medicare officials will have the final say in which make the list, but it’s likely to include high-spend drugs like blood thinners and medicines to control Type 2 diabetes, a Bloomberg Government analysis of the latest available spending data ...